Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy.

Kwong B, Liu H, Irvine DJ.

Biomaterials. 2011 Aug;32(22):5134-47. doi: 10.1016/j.biomaterials.2011.03.067. Epub 2011 Apr 22.

2.

Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.

Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ.

Cancer Res. 2013 Mar 1;73(5):1547-58. doi: 10.1158/0008-5472.CAN-12-3343. Epub 2013 Feb 22.

3.

Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.

Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ.

Clin Cancer Res. 2011 Apr 15;17(8):2270-80. doi: 10.1158/1078-0432.CCR-10-2888. Epub 2011 Mar 9.

4.

Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma.

Li Y, Yuan J, Yang Q, Cao W, Zhou X, Xie Y, Tu H, Zhang Y, Wang S.

Int J Nanomedicine. 2014 Dec 4;9:5683-700. doi: 10.2147/IJN.S73651. eCollection 2014.

5.

Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.

Qu X, Felder MA, Perez Horta Z, Sondel PM, Rakhmilevich AL.

Int Immunopharmacol. 2013 Dec;17(4):1141-7. doi: 10.1016/j.intimp.2013.10.019. Epub 2013 Nov 4.

6.

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.

Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, Mangsbo SM.

Cancer Immunol Res. 2014 Jan;2(1):80-90. doi: 10.1158/2326-6066.CIR-13-0067. Epub 2013 Oct 21.

7.

Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.

Jackaman C, Nelson DJ.

Cancer Immunol Immunother. 2012 Apr;61(4):549-60. doi: 10.1007/s00262-011-1120-5. Epub 2011 Oct 15.

PMID:
22002241
8.

Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models.

Jang JK, Khawli LA, Canter DC, Hu P, Zhu TH, Wu BW, Angell TE, Li Z, Epstein AL.

Cancer Immunol Immunother. 2016 May;65(5):511-23. doi: 10.1007/s00262-016-1813-x. Epub 2016 Mar 9.

PMID:
26960932
9.

Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.

Jérôme V, Graser A, Müller R, Kontermann RE, Konur A.

J Immunother. 2006 May-Jun;29(3):294-305.

PMID:
16699372
10.

Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

Stone GW, Barzee S, Snarsky V, Santucci C, Tran B, Langer R, Zugates GT, Anderson DG, Kornbluth RS.

PLoS One. 2009 Oct 8;4(10):e7334. doi: 10.1371/journal.pone.0007334.

11.

Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice.

Fan H, Zhang I, Chen X, Zhang L, Wang H, Da Fonseca A, Manuel ER, Diamond DJ, Raubitschek A, Badie B.

Clin Cancer Res. 2012 Oct 15;18(20):5628-38. doi: 10.1158/1078-0432.CCR-12-1911. Epub 2012 Aug 17.

12.

Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.

Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, Mahvi DA, Rakhmilevich AL.

Immunology. 2011 Feb;132(2):226-39. doi: 10.1111/j.1365-2567.2010.03357.x. Epub 2010 Oct 13.

13.

Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model.

Khong A, Brown MD, Vivian JB, Robinson BW, Currie AJ.

J Immunother. 2013 Sep;36(7):365-72. doi: 10.1097/CJI.0b013e31829fb856.

PMID:
23924788
14.

Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles.

Broos S, Sandin LC, Apel J, Tötterman TH, Akagi T, Akashi M, Borrebaeck CA, Ellmark P, Lindstedt M.

Biomaterials. 2012 Sep;33(26):6230-9. doi: 10.1016/j.biomaterials.2012.05.011. Epub 2012 Jun 9.

PMID:
22687756
15.

Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages.

Shi Y, Felder MA, Sondel PM, Rakhmilevich AL.

Mol Immunol. 2015 Aug;66(2):208-15. doi: 10.1016/j.molimm.2015.03.008. Epub 2015 Mar 28.

16.

The use of agonistic anti-CD40 therapy in treatments for cancer.

Khong A, Nelson DJ, Nowak AK, Lake RA, Robinson BW.

Int Rev Immunol. 2012 Aug;31(4):246-66. doi: 10.3109/08830185.2012.698338. Review.

PMID:
22804570
17.

Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses.

Dominguez AL, Lustgarten J.

Vaccine. 2010 Feb 3;28(5):1383-90. doi: 10.1016/j.vaccine.2009.10.153. Epub 2009 Nov 18.

18.

Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.

Fransen MF, Cordfunke RA, Sluijter M, van Steenbergen MJ, Drijfhout JW, Ossendorp F, Hennink WE, Melief CJ.

Vaccine. 2014 Mar 26;32(15):1654-60. doi: 10.1016/j.vaccine.2014.01.056. Epub 2014 Feb 7.

PMID:
24508038
19.

Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity.

Kluza E, Yeo SY, Schmid S, van der Schaft DW, Boekhoven RW, Schiffelers RM, Storm G, Strijkers GJ, Nicolay K.

J Control Release. 2011 Apr 10;151(1):10-7. doi: 10.1016/j.jconrel.2010.11.031. Epub 2010 Dec 3.

PMID:
21130819
20.

Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.

Alderson KL, Luangrath M, Elsenheimer MM, Gillies SD, Navid F, Rakhmilevich AL, Sondel PM.

Cancer Immunol Immunother. 2013 Apr;62(4):665-75. doi: 10.1007/s00262-012-1372-8. Epub 2012 Nov 15.

Supplemental Content

Support Center